Our study identifies a new direction for the treatment of CAVD, in which miR-34c suppresses STC1 and the JNK signaling pathway, leading to the alleviation of CAVD. The gene discussed is MAPK8; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.